Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial
Ke Cheng, Xiaoying Li, Wanrui Lv, Gang Zhao, Ruihan Zhou, Chen Chang, Heqi Yang, Ruizhen Li, Zhiping Li, Ye Chen, Cheng Yi, Ouying Yan, Chaoxin Xiao, Yi Zhang, Junjie Xiong, Zixin Huang, Weikang Shao, Xin You, Wenhao Guo, Du He, Wenwu Ling, Rui Wang, Bole Tian, Chengjian Zhao, Dan Cao · 2024
Read Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial by Ke Cheng, Xiaoying Li, Wanrui Lv, Gang Zhao, Ruihan Zhou, Chen Chang, Heqi Yang, Ruizhen Li, Zhiping Li, Ye Chen, Cheng Yi, Ouying Yan, Chaoxin Xiao, Yi Zhang, Junjie Xiong, Zixin Huang, Weikang Shao, Xin You, Wenhao Guo, Du He, Wenwu Ling, Rui Wang, Bole Tian, Chengjian Zhao, Dan Cao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11586424.txt.
Description
Cheng and a large team ran an early trial in twenty twenty-four of an immune drug plus chemo as first care for spread pancreas cancer. Such cancer has a grim outlook and immune drugs alone help little. Seventy-two folks got the pair at sites in China.
Mean survival was near nine months, with a third alive at one year. A third of tumors shrank and nine in ten were held in check. No grave drug harms were seen in the trial. A three-cell niche in tumor tissue flagged who gained most. Cell place, not just cell kind, may guide such care.
Catalog record
| CREATOR | Ke Cheng, Xiaoying Li, Wanrui Lv, Gang Zhao, Ruihan Zhou, Chen Chang, Heqi Yang, Ruizhen Li, Zhiping Li, Ye Chen, Cheng Yi, Ouying Yan, Chaoxin Xiao, Yi Zhang, Junjie Xiong, Zixin Huang, Weikang Shao, Xin You, Wenhao Guo, Du He, Wenwu Ling, Rui Wang, Bole Tian, Chengjian Zhao, Dan Cao |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |